Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya
Status:
COMPLETED
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The first study of doxycycline postexposure prophylaxis for cisgender women did not reduce incident STIs likely due to low use of doxycycline. Researchers will conduct a pilot study of once-weekly doxyxycline to prevent bacterial STIs among Kenyan cisgender women using PrEP for HIV prevention.
Phase:
PHASE4
Details
Lead Sponsor:
University of Washington
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)